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Although HER2-targeted therapies have dramatically improved the clinical outcome of 
HER2-positive breast cancer patients, innate and acquired resistance remains an 
important clinical challenge. New therapeutic approaches and diagnostic tools for 
identification, stratification and treatment of patients at higher risk of resistance and 
recurrence are therefore warranted. Here, we unveil a new mechanism controlling the 
oncogenic activity of HER2: heteromerization with cannabinoid receptor CB2R. We 
show that HER2 physically interacts with CB2R in breast cancer cells, and that the 
expression of these heteromers correlates with poor patient prognosis. The 
cannabinoid Δ9-tetrahydrocannabinol disrupts HER2-CB2R complexes by selectively 
binding to CB2R, which leads to 1) the inactivation of HER2 through disruption of 
HER2-HER2 homodimers, and 2) the subsequent degradation of HER2 by the 
proteasome via the E3 ligase c-CBL. This, in turn, triggers antitumor responses in vitro 
and in vivo. Selective targeting of CB2R transmembrane region 5 mimicked THC 
effects. Together, these findings define HER2-CB2R heteromers as new potential 
targets for antitumor therapies and biomarkers with prognostic value in HER2-positive 
breast cancer. 
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Significance 
There is a subtype of breast cancer characterized by the overexpression of the 
oncogene HER2. Although most patients with this diagnosis benefit from HER2-
targeted treatments, some of them do not respond to these therapies and others 
develop resistance with time. New tools are therefore warranted for the treatment of 
this patient population, and for early identification of those individuals at a higher risk of 
developing innate or acquired resistance to current treatments. Here, we show that 
HER2 forms heteromer complexes with cannabinoid receptor CB2R, that the 
expression of these structures correlates with poor patient prognosis, and that their 
disruption promotes antitumor responses. Collectively, our results support HER2-CB2R 
heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer.   
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\body 
Breast cancer is a very heterogeneous disease in terms of molecular markers, 
prognosis and treatments. According to all subclassification methods, there is a specific 
subtype that is characterized by overexpression of the human epidermal growth factor 
receptor 2 (HER2), which represents roughly 15-20% of all breast tumors (1, 2). HER2 
belongs to the ERBB (HER) receptor tyrosine kinase family, which consists of four 
members: HER1 (epidermal growth factor receptor, EGFR), HER2, HER3 and HER4. 
HER2 promotes oncogenic signaling by modulating the expression and activity of 
proteins controlling cell proliferation, differentiation, death, migration and angiogenesis. 
Activation of HER2 is achieved by ligand- or overexpression-induced dimerization with 
other members of the family, followed by transphosphorylation and 
autophosphorylation of the two constituents of the HER homo/heterodimer in their 
cytosolic kinase domains (3, 4). Overexpression of HER2 in some ways is a paradigm 
for the design of targeted therapies for the management of this subtype of tumors. 
Thus, trastuzumab, a recombinant humanized monoclonal anti-HER2 antibody, has 
significantly improved the outcome of these patients (1, 4, 5). Despite its efficacy in 
many HER2+ breast cancer cases, some patients do not respond to this treatment and 
others eventually progress. Identifying the molecular mechanisms underlying HER2 
activation (i.e. dimerization, trans and autophosphorylation) allowed the design of 
additional tools to overcome resistance to trastuzumab and improve the treatment of 
these tumors. For example, pertuzumab, another anti-HER2 monoclonal antibody, was 
designed to specifically target the dimerization domain of HER2, and lapatinib, a 
tyrosine kinase inhibitor, to selectively inhibit the trans and autophosphorylation of 
HER1 and HER2 (1, 4, 5). Simultaneous targeting of HER2 at different levels (i.e. 
combination of the aforementioned agents) is showing better clinical outcomes than 
anti-HER2 monotherapies, but some patients still present with either innate or acquired 
resistance (1, 5). Therefore, new/complementary therapeutic approaches are urgently 
needed to both identify and treat this patient population. 
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Cannabinoids, the active constituents of cannabis, produce antitumor 
responses in preclinical models of cancer, including HER2+ breast cancer (6-9). In 
most cases, the antitumor responses are produced by binding and activating 
cannabinoid receptors. CB1R and CB2R, the two cannabinoid receptors described so 
far, belong to the G protein-coupled receptor (GPCR) superfamily of membrane 
proteins. While CB1R, the main responsible for the psychoactive effects of cannabis, is 
widely expressed throughout the body and especially abundant in the central nervous 
system, CB2R, in healthy individuals, is mainly restricted to elements of the immune 
system. However, increasing evidence shows that the expression of this receptor is 
augmented in many pathological states, including cancer (6-8). In fact, the preclinical 
research conducted so far in preclinical models of HER2+ breast cancer points to CB2R 
as the main target of cannabinoid antitumor action (10, 11). 
Here, we aimed at getting a deeper insight into the mechanisms of HER2 
activation/inactivation, to provide new potential targets for treatment of HER2+ tumors. 
Specifically, we studied the functional relevance of a recently described heteromer 
between HER2 and the cannabinoid receptor CB2. We have previously reported the 
presence of these complexes in HER2+ breast cancer tumors (12), but their role in 
HER2 function is as yet unknown. In this context, the main goal of this study was to 
determine the role of HER2-CB2R heteromers in HER2+ breast cancer pathology, and, 
overall, whether these structures could be new targets for anticancer treatments. 
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Results  
HER2-CB2R heteromer expression correlates with poor patient prognosis. We 
have previously described that CB2R promotes HER2 pro-oncogenic signaling, and that 
these two membrane receptors physically interact in HER2+ breast cancer cells and 
tissue (12). However, the functional relevance of these heteromers is completely 
unknown. To evaluate their role in breast cancer, we first analyzed the expression of 
these complexes in a series of 57 human HER2+ breast cancer biopsies obtained at 
the time of first diagnosis, before any treatment (TMA #1 in the Methods section). 
Proximity Ligation Assays (PLAs) (Fig. 1A) showed that higher HER2-CB2R expression 
in the tumors is associated to lower disease-free patient survival (DFS) (Fig. 1B), as 
well as to higher spread to regional lymph nodes and Ki67 overexpression (Table 1). 
To further validate these observations, we performed similar analyses in an additional 
TMA containing 39 human high-grade HER2+ ductal breast cancer samples obtained 
before any treatment (TMA #2 in the Methods section). High HER2-CB2R heteromer 
expression was also associated to poor patient prognosis, specifically lower disease-
free and overall patient survival (Figs. 1C,D). Positive and negative controls for HER2-
CB2R heteromer expression are shown in SI Appendix, Figs.S1A-D. The separate 
analysis of either HER2 or CB2R by immunohistochemistry confirmed two issues: first, 
that increased heteromer expression is not just a consequence of individual receptor 
overexpression. Thus, similar HER2-CB2R heteromer levels were found in tumors with 
low, medium or high HER2 expression (SI Appendix, Fig. S1E), as well as with no, low, 
medium or high CB2R expression (SI Appendix, Fig. S1F). Second, that HER2-CB2R 
heteromer expression is a better prognostic marker than HER2 alone or CB2R alone. 
Thus, no association between HER2 expression and disease-free survival was found in 
TMA #1 (SI Appendix, Fig. S2A); and, for CB2R expression, although there seemed to 
be an association trend with disease-free survival, it did not reach statistical 
significance either (SI Appendix, Fig. S2B). In addition, we analyzed heteromer 
expression in two pairs of patient-derived xenografts (PDX). Each pair consisted of one 
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PDX generated from the patient’s primary tumor, and another PDX generated from the 
corresponding metastasis (in the liver in one case, and in a lymph node in the other). 
Consistent with the idea that HER2-CB2R complexes correlate with poor patient 
prognosis, in both cases we observed significantly higher heteromer expression in the 
metastatic tissue with respect to the corresponding primary tumor (Figs. 1E,F). 
Together, these results show that HER2-CB2R heteromers are specific receptor 
complexes present in HER2+ breast cancer tissue, and are associated to tumor 
recurrence and spreading. 
 
THC disrupts HER2-CB2R complexes and impairs HER2+ breast cancer cell 
viability. Since HER2-CB2R heteromer expression seems to be linked to pro-
oncogenic processes ((12) and Fig. 1), we next studied whether these complexes could 
be targets for antitumor therapies. It has been previously described that CB2R 
activation in different models of HER2+ breast cancer leads to cancer cell death by 
apoptosis, and inhibition of tumor growth, angiogenesis and metastasis (10, 11). To 
determine if HER2-CB2R heteromers are involved in this cannabinoid antitumor action, 
we analyzed their expression in response to 9-tetrahydrocannabinol (THC, the main 
bioactive constituent of cannabis). We first used HEK293 cells transiently transfected 
with HER2 and CB2R as a model. In this system, we confirmed the formation of HER2-
CB2R complexes by Bioluminescence Resonance Energy Transfer (BRET) (Figs. 
2A,B). The heteromer signal significantly decreased upon THC treatment (Fig. 2C). 
The cannabinoid-induced decrease in both HER2-CB2R and cell viability relied on 
CB2R activation, as pointed by the preventive effect of the CB2R-selective antagonist 
SR144528 (SR2, Figs. 2C,E). In addition, and supporting the idea that HER2-CB2R 
heteromers are unique signaling structures, we observed that upon exposure to THC, 
CB2R coupling shifts to a different set of heterotrimeric G proteins. Thus, in cells only 
expressing CB2R, THC induced the coupling of the receptor to Gq/11, while it promoted 
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the coupling to Gi and Gz when HER2 and CB2R were co-expressed (SI Appendix, Fig. 
S3).  
To determine whether the effects observed in HEK293 cells also occur in more 
physiological settings, we run a series of experiments in two different human HER2+ 
breast cancer cell lines (BT474 and HCC1954). THC decreased the viability of both cell 
lines in a concentration-dependent manner (Fig. 2F), an effect that was again 
prevented by SR2 (Fig. 2G). The interaction between HER2 and CB2R in these cells 
was then analyzed by co-immunoprecipitation upon overexpression of an HA-tagged 
form of CB2R. THC treatment diminished the amount of CB2R that co-
immunoprecipitated with HER2 in both cell lines, which points to a cannabinoid-induced 
disruption of the heteromer (Fig. 2H). The decrease in HER2-CB2R complexes was not 
due to a reduction in the receptors’ expression as they remained unchanged after a 4h 
THC treatment (Fig. 2H). To further support the idea that THC disrupts HER2-CB2R 
heteromers, we performed PLAs in the two breast cancer cell lines in native conditions 
(i.e., under no overexpression of HER2 or CB2R). Data showed that THC decreases 
the amount of these complexes by activating CB2R (Figs. 2I,J).  
 
HER2-CB2R heteromer disruption by THC hampers HER2 activation. HER2 
activation occurs upon dimerization with other members of the HER family, followed by 
trans and autophosphorylation of the intracellular domains of each protomer (13). We 
analyzed whether disruption of the HER2-CB2R heteromer by THC had any effect on 
this activation process. First, and to determine which specific HER dimers may be 
affected by HER2-CB2R disruption, we evaluated the expression of the four members 
of the HER family in the two HER2+ cell lines used in our studies. In addition to HER2, 
we found HER1 and HER3 overexpression in at least one of them when compared to a 
luminal (MCF7) or a basal (MDA-MB-231) breast cancer cell line (Fig. 3A). We 
therefore studied the effect of THC on HER2-HER1, HER2-HER2 and HER2-HER3 
heteromers in HCC1954 cells. Neither HER2-HER1 nor HER2-HER3 complexes were 
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affected by cannabinoid treatment (Figs. 3B,C). In contrast, THC significantly 
diminished the amount of HER2-HER2 homodimers (Figs. 3B,C), and this effect was 
prevented by SR2 (Figs. 3D,E). HER2-HER2 homodimer reduction upon THC 
challenge, and involvement of CB2R in this effect, were further confirmed by BRET in 
HEK293 HER2-CB2R cells (Fig. 3F).  As expected, THC produced no such action in 
HEK293 cells lacking CB2 receptors (Fig. 3G). In line with these observations, THC 
decreased the levels of HER2 phosphorylated in Tyr1248 (Figs. 3H,I), one of the main 
autophosphorylation sites in this receptor. Taken together, these observations 
demonstrate that HER2-CB2R heteromer disruption by THC hampers HER2 activation 
by interfering with its homodimerization. 
 
THC induces HER2-CB2R heteromer disruption and HER2 degradation in vitro 
and in vivo. Cannabinoid challenge produced a marked decrease in the levels of 
activated (phospho-Tyr1248) HER2 (Figs. 3H,I and Figs. 4A,B), that was followed by a 
decrease in the total levels of HER2 (Figs. 4A,B). This effect was prevented by 
blockade of CB2R (Fig. 4C), and was not due to inhibition of gene transcription, as 
indicated by the observation that HER2 mRNA levels remained unchanged (Fig. 4D). 
These results suggest that THC produces both an impairment of HER2 pro-oncogenic 
activity, and the triggering of anti-tumoral signaling through CB2R activation. In line with 
this notion, inactivation of both ERK and AKT was observed 24 h after THC treatment, 
and this was prevented by CB2R pharmacological blockade as well as by HER2 knock-
down, which reduced pERK and pAKT per se (SI Appendix, Fig. S4).    
Importantly, THC also produced the disruption of HER2-CB2R heteromers in 
vivo, an effect that was associated to HER2 degradation, and antitumor responses. 
Thus, THC significantly decreased the growth of orthotopic xenografts generated in 
immunodeficient mice by injection of HCC1954 cells (Fig. 4E), and tumors from the 
THC-treated group showed significantly reduced HER2 protein levels (Figs. 4F,G), as 
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well as significantly reduced HER2-CB2R and HER2-HER2 PLA signal (Figs. 4H,I), 
when compared to vehicle-treated animals. 
One of the main mechanisms of intracellular protein degradation is proteolytic 
hydrolysis by the proteasome (14). Blockade of the proteasome system with lactacystin 
prevented the decrease of HER2 levels induced by THC in BT474 breast cancer cells 
(Figs. 5A,B). We performed similar experiments in HCC1954 cells, but they showed 
hypersensitivity to proteasome inhibition and died in response to low concentrations of 
lactacystin. THC also increased the levels of ubiquitinated HER2 (Fig. 5C). The main 
E3 ligases reported so far to be responsible for HER2 degradation are CHIP and c-CBL 
(15). While cannabinoid treatment did not modify the levels of the former, it significantly 
increased the amount of c-CBL in BT474 and HCC1954 cells (Figs. 5D,E). Moreover, 
THC augmented the extent of HER2 phosphorylation at Tyr1112, the residue that is 
specifically recognized by c-CBL and triggers HER2 poly-ubiquitination (16) (Fig. 5F). 
Involvement of c-CBL in HER2 degradation was further supported by genetic blockade. 
siRNA-driven targeting of this E3 ligase prevented THC-induced decrease of total 
HER2 levels in the two breast cancer cell lines tested (Figs. 5G,H).  
Collectively, these findings demonstrate that THC disrupts HER2-CB2R 
heteromers, blocks HER2 activation and promotes its degradation through the 
proteasome system via c-CBL activation, which results in antitumor responses.   
 
HER2-CB2R heteromer disruption by targeting CB2R TM5 mimics THC effects. To 
determine whether the effects described above were THC-specific or could also be 
produced by other tools that disrupt HER2-CB2R heteromers, we used two different 
experimental approaches aimed at blocking the physical interaction between HER2 
and CB2R. First, and to determine which part of the cannabinoid receptor is involved in 
the interaction with HER2, we generated a series of truncated proteins containing the 
N-terminal domain of CB2R, followed by one of the seven transmembrane (TM) 
domains of the receptor and its C-terminal domain. All constructs contained an HA tag 
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in the N-terminal domain (Fig. 6A). Co-immunoprecipitation assays in HEK293 cells 
cotransfected with HER2 and the different CB2R constructs showed a potential 
interaction between HER2 and TMs 1, 3, 4 and 5 of CB2R (Fig. 6B). To determine 
which of them was more plausible to participate in the physical interaction between the 
two receptors, we performed Bimolecular Fluorescence Complementation (BiFC) 
assays in HEK293 cells (Fig. 6C). A fluorescent, proximity-evoked signal was observed 
when the HER2 fusion protein was co-transfected with the CB2R fusion protein and the 
constructs containing CB2R TMs 1, 2, 3, 6 and 7 (Fig. 6D). This signal was significantly 
reduced upon cotransfection with CB2R TMs 4 and 5 (Fig. 6D), which is indicative of 
heteromer disruption. Since TM5 has been previously described to be involved in 
interactions between GPCRs (17-19), we focused our studies on this specific 
transmembrane domain. A TM5-targeted peptide (CB2R TAT-TM5) was then used to 
prevent the association between CB2R and HER2. The use of this type of peptides has 
been widely reported in the literature, and it is broadly accepted as a tool for disrupting 
GPCR-GPCR interaction (20, 21). BiFC experiments confirmed that this tool selectively 
blocks the formation of HER2-CB2R heteromers (Fig. 6E). Thus, the fluorescent signal 
indicative of the presence of HER2-CB2R heteromers disappeared when cells were 
incubated with the CB2R TAM-TM5 peptide, and not when they were challenged with a 
D44R TAT-TM5-targeted peptide (used as negative control) (Fig. 6E). Similar data 
were obtained when PLA assays were carried out in native untransfected HER2+ 
breast cancer cells (Fig. 7A), i.e., a significant decrease in the dotted fluorescent signal 
corresponding to the heteromers appeared upon CB2R TAT-TM5 treatment, which was 
not evident when the D44R TM5 peptide was used (Figs. 7A,B). Of interest, and as 
observed for THC, disruption of HER2-CB2R heteromers by the CB2R TAT-TM5 
peptide produced 1) HER2 inactivation, as demonstrated by a dramatic decrease in the 
formation of HER2-HER2 homodimers (Figs. 7C,D), and in the levels of 
phosphorylated HER2 (Figs. 7E,F); 2) HER2 degradation, evidenced by a marked 
reduction in total HER2 protein levels (Figs. 7E,F); and 3) a concomitant decrease in 
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the viability of HER2+ breast cancer cells (Fig. 7G) that was not observed in wild-type 
HEK293 cells, which do not express either HER2 or CB2R (Fig. 7G). Altogether, these 
results show that disruption of HER2-CB2R heteromers, either with THC or with other 
tools aimed at interfering with the physical interaction between CB2R TM5 and the 
transmembrane domain of HER2, dramatically impair the viability of HER2+ breast 
cancer cells.             
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Discussion 
Here, we describe a new mechanism controlling the activity of HER2 that may 
constitute a new target for antitumor treatments. Specifically, we observed that HER2 
physically interacts with a membrane receptor that does not belong to the HER family 
(cannabinoid receptor CB2R), thus forming HER2-CB2R heteromers, and that 
disrupting these complexes triggers the inactivation and degradation of HER2, 
promoting in turn antitumoral responses. The HER2-CB2R heteromers described herein 
fulfill the three criteria required for demonstrating receptor heteromerization (20, 21): 
first, the heteromer components (HER2 and CB2R) interaction is demonstrated by 
proximity-based techniques and co-immunoprecipitation; second, HER2-CB2R 
heteromers exhibit properties distinct from those of the protomers, as demonstrated by 
the coupling of CB2R to different heterotrimeric G proteins depending on whether it is 
part of the heteromer or not; and third, heteromer disruption leads to a loss of 
heteromer-specific properties, as demonstrated by the fact that while HER2-CB2R 
complexes are linked to pro-oncogenic events (12), disruption of the heteromers leads 
to antitumor responses. 
Interaction of HER2 with other membrane receptor tyrosine kinases is a 
common and well described process. Dimerization with other members of the HER 
family, for example, is a necessary step for HER activation, and in fact some drugs 
have been already designed to interfere with this step and block the subsequent pro-
oncogenic signaling (4). An increasing number of studies demonstrate that GPCRs 
also interact physically between them, generating unique signaling platforms (GPCR 
heteromers) with physio-pathological implications different than that of the constituting 
monomers. Most of them have been described in the central nervous system, and are 
becoming potential therapeutic targets for disorders such us addiction, pain, 
Parkinson’s disease and schizophrenia (21-23). Heteromers between cytokine and 
adrenergic receptors have also been described, with implications in blood pressure 
regulation (21, 23), or between different GPCRs in distinct endocrine systems, which 
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may constitute new targets for endocrine-related disorders (24). Cannabinoid receptors 
in particular have been long described as constituents of particular GPCR receptor 
heteromers. Thus, CB1R physically interacts with CB2R (25), serotonin (26), adenosine 
(22, 27), opioid (28), orexin (29) and angiotensin (30) receptors, and with the 
cannabinoid-related orphan receptor GPR55 (31). CB2R, on the other hand, has been 
shown to form heteromers with GPR55 (32, 33) and CXCR4 (34, 35). Although several 
RTK-RTK heteromers and GPCR-GPCR heteromers have been previously described, 
there are very few examples of physical interaction between RTKs and GPCRs yet. 
Transactivation of RTKs by GPCRs and vice versa has been reported, and in some 
cases physical interactions suggested, but no solid proof of the existence of such 
heteromers has been provided in most cases (36). Usually, colocalization, 
coimmunoprecipitation and pharmacological transmodulation of the protomers in non-
native cell systems is the only evidence suggesting the presence of the heteromer, but 
this is clearly insufficient. Colocalization does not provide enough subcellular resolution 
to establish close proximity, and even coimmunoprecipitation can occur with receptors 
too far apart to directly modulate one another. Transactivation is no doubt a very 
interesting pharmacological process, but demonstrating the existence of receptor 
heteromers has additional importance in terms of providing new drugable therapeutic 
targets. To the best of our knowledge, the best characterized RTK-GPCR heteromer is 
that formed by HER2 and β2-adrenergic receptors in the heart, which seems to be 
essential for cardiac homeostasis (37); by fibroblast growth factor receptor and 
adenosine A2A receptors (38) or serotonin 5-HT1A receptors (39), which play important 
roles in synaptic plasticity; and by EGFR and GPR54, which seem to promote breast 
cancer cell invasiveness (40). Here, we comprehensively describe the existence of 
heteromers between HER2 and CB2R, and provide compelling evidence showing that 
their disruption promotes antitumoral responses both in vitro and in vivo, which may 
constitute a new strategy to treat HER2+ breast tumors. It is tempting to speculate that 
other HER2-overexpressing tumors such as gastric or gastroesophageal 
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adenocarcinomas (41) may express similar CB2R-HER2 heteromers, and therefore 
respond in a similar way to treatments aimed at breaking up these complexes.  
Our previous work had shown that, in the absence of exogenously applied 
cannabinoids, CB2R plays a protumoral role in HER2+ contexts (12). In line with that 
study, here we report that heteromer expression correlates with poor patient prognosis. 
On the other hand, there is solid evidence that pharmacological activation of CB2R 
produces antitumoral responses in HER2+ preclinical settings (10, 11). Considering all 
these observations, we propose the following model for HER2-CB2R function in breast 
cancer (Fig. 8): under no pharmacological treatment, HER2+ breast cancer cells 
express high levels of HER2, which upregulate the expression of CB2R via the 
mechanisms described in (12). HER2 and CB2R then form heteromers in the plasma 
membrane, thereby protecting HER2 from degradation and favoring its canonical 
oncogenic signaling, resulting in pro-tumoral responses (Fig. 8A). When cells are 
exposed to THC (or to other tools that prevent HER2-CB2R interaction), the two 
receptors physically separate. In addition, HER2-CB2R disruption triggers inactivation 
of HER2 (by breaking HER2-HER2 homodimers) and increases its susceptibility to 
degradation. As a final consequence of HER2 degradation and CB2R activation, an 
antitumor response is produced (Fig. 8B). The experiments we have conducted clearly 
show a direct impact of THC on the viability of cancer cells in culture and also in vivo. 
However, we cannot rule out the involvement of other cell types in the full antitumor 
response induced by THC. For example, immune cells and endothelial cells express 
CB2R as well, and it is reasonable to speculate that they may be affected by THC. In 
fact, it has been previously demonstrated, for example, that THC impairs tumor 
angiogenesis by blocking endothelial cell migration, and blood vessel formation and 
elongation (reviewed in (42)). Of note, antitumor responses upon CB2R activation have 
also been described in non-HER2+ contexts. It would be interesting to analyze whether 
in those situations CB2R acts as a monomer in the plasma membrane or if it forms 
heteromers with other RTKs like HER1 (EGFR), which is overexpressed in many 
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different types of tumors (41). In favor of the latter, Elbaz et al. recently reported that 
CB2R impairs oncogenic EGF/EGFR signaling in ER+ breast cancer cells (43). 
Although not proved, the authors suggested that EGFR and CB2R may be forming 
complexes, and that CB2R activation might disrupt them (43). In addition, and similarly 
to what we observed here, pharmacological activation of CB1R induced the death of 
prostate cancer cells in culture, an effect that was accompanied by a significant 
downregulation of EGFR (44), and co-expression of EGFR with CB1R was associated 
to poor patient prognosis in this type of cancer (45). These observations demonstrate a 
functional interaction between another cannabinoid receptor (CB1R) and another 
member of the HER family (HER1), that could be due to a mere transactivation 
processes or to a physical interaction similar to that described here between CB2R and 
HER2.  
In summary, our findings unveil a new mechanism of regulation of HER2 
activity, and support HER2-CB2R heteromers as new therapeutic targets for the 
management of HER2+ breast cancer. Although THC efficiently achieves heteromer 
disruption, our data set the bases for the design of new antitumor drugs aimed at 
breaking this interaction. In addition, it would be interesting to design an alternative 
method to detect and quantify these heteromers in human samples. Thus, anti-HER2-
CB2R antibodies or similar tools would allow not only corroboration of the prognostic 
value described herein but also an easy transfer of this knowledge to the clinical 
practice. 
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Materials and Methods 
Cell viability assays. Cells were seeded at a density of 5000/cm2 in 10% FBS-
containing medium. Twenty-four hours later, they were serum starved overnight, and 
then treated with THC for 24h. Cells were then fixed and stained with a crystal violet 
solution (0.1% crystal violet, 20% methanol in H2O) for 20 minutes. After intensive 
washing with water, the stained cells were solubilized in methanol and absorbance 
measured at 570nm. 
Cell cultures and transfections. Human breast adenocarcinoma cell lines HCC1954 
(CRL-2338™), BT474 (HTB-20™), MCF7 (HTB-22™), MDA-MB-231(HTB-26™) and 
the human embryonic kidney cell line HEK293T (CRL-1573™) were purchased from 
American Type Culture Collection (ATCC, Barcelona, Spain). They were all 
authenticated by STR profiling (Genomics core facility at “Alberto Sols” Biomedical 
Research institute, Madrid, Spain), and routinely tested for mycoplasma contamination. 
Cells were cultured in RPMI (HCC1954, BT474), MEM (MCF7) or DMEM (MDA-MB-
231, HEK293T), supplemented with 10% FBS, 1% penicillin / streptomycin, and BT474 
and MCF7 cells with 10ug/mL insulin as well. They were all maintained at 37 ºC in an 
atmosphere of 5% CO2. 
For cell cultures experiments, THC (THC Pharm GmbH, Frankfurt, Germany) 
was dissolved in DMSO. Unless otherwise indicated, the concentration used was 3µM 
for HCC1954 cells and 4μM for BT474 and HEK293T cells. The CB2R-selective 
antagonist SR144528 (SR2) (Tocris Bioscience, Abingdon, UK) and lactacystin 
(Calbiochem, San Diego, CA) were dissolved in DMSO, and added to the cell cultures 
(1µM) 1h prior THC.  
Expression vectors were transiently transfected with Fugene HD Transfection 
Reagent (Promega, Madison, WI) in human breast cancer cells, and PolyEthylenImine 
(PEI) (Sigma-Aldrich, St Louis, MO) in HEK293T cells. Transient genetic knock-down 
was done by selective siRNAs transfection with DharmaFECT 1 Transfection reagent 
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(Dharmacon, Lafayette, CO). Selective siRNAs to knock down human c-CBL were 
purchased from Dharmacon as a SMARTpool. These reagents combine four SMART 
selection-designed siRNAs into a single pool, which guarantees an efficiency of 
silencing of at least 75%. Sequences were: 5’-AAUCAACUCUGAACGAAA-3’, 5’-
GACAAUCCUCACAAUAAA -3’, 5’-UAGCCCACCUUAUAUCUUA-3’, and 5’-
GGAGACAUUUCGGAUUA-3’. The control (non-targeted) siRNA was purchased from 
Thermo-Fisher Scientific (Waltham, Massachusetts). 
 
Western blot analysis. Cells and tumors were lysed on RIPA buffer supplemented 
with 1mM sodium orthovanadate, 1mM PMSF, 2µg/µL aprotinin and 2µg/µL leupeptin 
(Sigma-Aldrich). Total lysates were resolved by SDS-PAGE, and electrophoretically 
transferred to PVDF membranes. After blocking with 5% w/v non-fat dry milk in TBST, 
membranes were incubated with the following antibodies overnight at 4ºC: rabbit 
polyclonal anti-HER2 (C-18, Santa Cruz Biotechnology, Santa Cruz, CA); mouse 
monoclonal anti-HER2 (44E7), rabbit polyclonal anti-phospho HER2 (Tyr1248) (#2247) 
(Cell Signaling Technology, Danvers, MA); rabbit polyclonal anti-HER1 (06-847, EMD 
Millipore, Darmstadt, Germany); rabbit polyclonal anti-HER3 (1B2E, #4754, Cell 
Signaling Technology); rabbit polyclonal anti-HER4 (C-18, Santa Cruz Biotechnology); 
rabbit polyclonal anti-HA Tag (C29F4, Cell Signaling Technology); mouse monoclonal 
anti-β-actin (AC-74, Sigma-Aldrich); mouse monoclonal anti-c-CBL (clone 17, BD 
Bioscience, San Jose, CA); mouse monoclonal anti-STUB1 (CHIP) (ab2917, Abcam, 
Cambridge, UK); and mouse monoclonal anti-ubiquitin (P4D1, Santa Cruz 
Biotechnology). Secondary antibodies were chosen according to the species of origin 
of the primary antibodies, and detected by enhanced chemiluminescence system (Bio-
Rad, Hercules, CA). β-Actin was used as loading control. Densitometric analysis of the 
relative expression of the protein of interest vs the corresponding control (β-Actin or 
total HER2) was performed with ImageJ software. 
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Co-immunoprecipitation assays. HCC1954 and BT474 cells were transiently 
transfected with pcDNA3.1-HA-hCB2R (UMR cDNA Resource Center, University of 
Missouri, Rolla, MO) or the corresponding empty vector (pcDNA3) (InVitrogen, 
Barcelona, Spain) with Fugene HD Transfection Reagent (Promega). HEK293 cells 
were transiently co-transfected with pcDNA3-HER2, pcDNA3.1-HA-hCB2R or pcDNA3 
containing the different CB2R trasmembrane constructs (see below), using PEI (Sigma-
Aldrich). Forty-eight hours after transfection, cells were lysed on a buffer containing 40 
mM Hepes pH 7.5, 120 mM NaCl, 1mM EDTA, 10mM sodium pyrophosphate, 10mM 
sodium glycerophosphate, 50mM sodium fluoride, 0.5mM sodium orthovanadate, 0.3% 
CHAPS, and suplemented with 1mM benzamidine and 0.1mM PMSF. Cell lysates 
(1mg) were incubated with anti-HER2 antibody (C-18, Santa Cruz Biotechnology) 
covalently coupled to protein G-sepharose (GE Healthcare, Uppsala, Sweden) 
overnight at 4ºC on a rotating wheel. Immunoprecipitates were washed with lysis buffer 
and Hepes buffer (25mM Hepes pH 7.5 and 50mM KCl), resuspended in sample 
buffer, and filtered through a 0.22-µm-pore-size Spin-X filter (Sigma-Aldrich). 2-
Mercaptoethanol was then added to a concentration of 1% (v/v), and samples resolved 
by SDS-PAGE and transferred to PVDF membranes. Membranes were blotted with 
anti-HA antibody (Cell Signaling Technology). 
 
Ubiquitination assays. Cells were lysed after 4h of THC or DMSO treatment using 
RIPA buffer supplemented with 1mM sodium orthovanadate, 0.1mM PMSF and 20mM 
NEM. Cell lysates (1mg) were immunoprecipitated with an anti-HER2 antibody (C-18, 
Santa Cruz Biotechnology) or pre-immune IgG overnight at 4ºC on a rotating wheel. 
Cell lysates were then incubated with protein G-sepharose and then washed in RIPA 
buffer lysis. Finally, immunoprecipitates were resuspended in sample buffer containing 
2-mercaptoethanol. Samples were then resolved and electrophoretically transferred to 
PVDF membranes, and blotted with mouse monoclonal anti-ubiquitin antibody (P4D1, 
Santa Cruz Biotechnology). 
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Real-time quantitative PCR (qPCR). RNA was isolated with Trizol Reagent 
(Invitrogen) and cDNA was obtained with Transcriptor Reverse Transcriptase (Roche 
Applied Science, Basel, Switzerland). Real-time quantitative PCR assays were 
performed using the FastStart Master Mix with Rox (Roche). The primers used for 
ERBB2 (HER2) were: Forward 5´-GGGAAACCTGGAACTCACCT-3´; Reverse 5´-
CCCTGCACCTCCTGGATA-3´. Each value was adjusted by using ACTB (Forward: 5´-
CCAACCGCGAGAAGATGA-3´; Reverse 5´-CCAGAGGCGTACAGGGATAG-3) and 
GUSB (Forward 5´-CGCCCTGCCTATCTGTATTC-3´; Reverse 5´-
TCCCCACAGGGAGTGTGTAG-3´) levels as references. 
 
Immunohistochemistry (IHC). Tissue sections were subjected to a heat-induced 
antigen retrieval step prior to exposure to a rabbit polyclonal anti-CB2R (101550, 
Cayman Chemical, Ann Arbor, MI) or a rabbit anti-HER2 primary antibody 
(HercepTest™, DAKO, Glostrup, Denmark). Immunodetection was performed using the 
Envision method with DAB as the chromogen (DAKO). To quantify CB2R expression in 
the TMA, cases were scored as 0 (no staining), 1 (weak staining), 2 (moderate 
staining), or 3 (high staining). HER2 staining was scored in accordance with 
HercepTestTM manufacturer’s guidelines. 
 
In situ Proximity Ligation Assays (PLAs). For PLAs in the TMA and in sections of 
the patient-derived xenografts (PDX), samples were deparaffinized and submitted to 
heat-induced antigen retrieval in sodium citrate buffer (10mM sodium citrate, 0.05% 
Tween-20, pH 6.0). TMA-, PDX- and xenograft-derived slices were permeabilized with 
PBS containing 0.01% Triton X-100. For PLAs in cell cultures, cells were seeded on 
glass coverslips at 5000/cm2. After overnight serum starvation, cells were treated for 4h 
with THC, TAT-TM peptides (4 µM) or the corresponding vehicle. They were then fixed 
in 4% paraformaldehyde, and permeabilized with 0.05% Triton X-100. 
22 
 
Heteromers were detected by using the Duolink in situ PLA detection kit 
(Sigma-Aldrich) following manufacturer’s instructions. For detection of HER2-CB2R 
heteromers, cells were incubated with equal amounts of a rabbit anti-CB2R antibody 
(101550, Cayman Chemical) directly linked to a plus PLA probe, and a rabbit anti-
HER2 antibody (C-18, Santa Cruz Biotechnology) directly linked to a minus PLA probe. 
For detection of other HER2 heteromers, cells were incubated with a mixture of equal 
amounts of a mouse anti-HER2 antibody (44E7, Cell Signaling Technology) and rabbit 
anti-HER1 antibody (06-847, EMD Millipore) for HER2-HER1 detection, or with a rabbit 
anti-HER3 antibody (1B2E, Cell Signaling Technology) for HER2-HER3 detection. A 
plus anti-rabbit PLA probe and a minus anti-mouse PLA probe were used. For negative 
controls, one of the primary antibodies was omitted. Ligation and amplification was 
done with In Situ Detection Reagent Red (Sigma-Aldrich) and slices were mounted in 
DAPI-containing mounting medium. Samples were analyzed in a Leica SP2 confocal 
microscope (Leica Microsystems, Mannheim, Germany) and processed with Image J 
software. Heteromer expression was calculated as the number of red fluorescence 
spots (indicating that receptors are within sufficient proximity)/total cells in the field. 
Representative images for each condition were prepared for figure presentation by 
applying brightness and contrast adjustments uniformly using Adobe Photoshop CS5. 
 
Fusion proteins for BRET and BIFC assays. Sequences encoding amino acid 
residues 1-155 and 156-238 of YFP Venus protein were subcloned in pcDNA3.1 vector 
to obtain YFP Venus hemitruncated proteins. The human cDNAs for HER2, 
cannabinoid (CB2R), dopamine (D44R) and Ghrelin (GHS-R1a) receptors, cloned into 
pcDNA3.1, were amplified without their stop codons using sense and antisense primers 
harboring: EcoRI and BamHI sites to clone CB2R and GHS-R1a, XhoI and EcoRI to 
clone D44R or NheI and XhoI to clone HER2. The amplified fragments were subcloned 
to be in frame with restriction sites of pRLuc-N1 (PerkinElmer, Wellesley, MA) or 
pEYFP-N1 (enhanced yellow variant of GFP; Clontech, Heidelberg, Germany) vectors, 
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to generate plasmids that express proteins fused to Rluc or YFP on the C-terminal end 
(HER2-Rluc, D44R-Rluc, HER2-YFP, CB2R-YFP, or GHS-R1a-YFP).  For BiFC 
experiments, the cDNA for HER2, CB2R and D44R were also subcloned into 
pcDNA3.1-nVenus or pcDNA3.1-cVenus to generate a plasmid that expresses the 
receptor fused to the hemitruncated nYFP Venus or hemitruncated cYFP Venus on the 
C-terminal end of the receptor (HER2-nVenus, D44-nVenus, CB2R-cVenus). 
 
CB2R transmembrane mutants. A pCDNA3-HA-CB2R plasmid was used as template 
for the generation of seven mutants containing a HA tag, followed by the N-terminal 
domain, one transmembrane domain and the C-terminal domain of CB2R. To assure 
the correct orientation of the resulting peptides, in constructs containing even-
numbered transmembrane domains, the sequences corresponding to the 
transmembrane domains were reversed. The primers used to generate these 
constructs are shown in SI Appendix, Table S1.  
 
HIV TAT-TM peptides. Peptides containing the amino acid sequence of CB2R and 
D4R transmembrane (TM) domains 5 were used as heteromer disrupting agents. To 
allow intracellular delivery and the correct membrane orientation, they were fused (at 
the C-terminus domain) to the cell-penetrating HIV TAT peptide. Their resulting TAT-
TM peptides were: 
TM5-TAT CB2R: DYLLSWLLFIAFLFSGIIYTYGHVLWYGRKKRRQRRR 
TM5-TAT D4R: YVVYSSVCSFFLPCPLMLLLYWATFYGRKKRRQRRR. 
They were synthetized at the Peptide Synthesis Facility at University Pompeu Fabra 
(Barcelona, Spain). 
 
Bioluminescence Resonance Energy Transfer (BRET) assays. HEK293 cells were 
transiently co-transfected with a constant amount of a cDNA encoding HER2 or D44R 
fused to Rluc protein (HER2-Rluc, D44R-Rluc) as BRET donor, and with increasing 
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amounts of a cDNA of the other receptor fused to YFP (CB2R-YFP, HER2-YFP, GHS-
R1a-YFP) as BRET acceptor. For quantification of protein-YFP expression, 
fluorescence at 530nm was analyzed in a Fluo Star Optima Fluorimeter (BMG 
Labtechnologies, Offenburg, Germany). Fluorescence of cells expressing the BRET 
donor only was subtracted from these measurements. BRET signal was analyzed 1 
minute after addition of the bioluminescent substrate coelenterazine H (5 μM, 
Molecular Probes, Eugene, OR) with a Mithras LB 940. To quantify protein-Rluc 
expression, luminescence was determined 10 minutes after addition of 5 μM 
coelenterazine H. The net BRET is defined as [(long-wavelength emission)/(short-
wavelength emission)]-Cf where Cf corresponds to [(long-wavelength emission)/(short-
wavelength emission)] for the Rluc construct expressed alone in the same experiment. 
BRET is expressed as milli BRET units (mBU; net BRET x 1,000). In BRET curves 
BRET was expressed as a function of the ratio between fluorescence and 
luminescence x 100 (YFP/Rluc). To calculate maximum BRET (BRETmax) from 
saturation curves, data were fitted using a non-linear regression equation and 
assuming a single phase with GraphPad Prism software (San Diego, CA, USA). 
 
Bimolecular Fluorescence Complementation assays (BiFC). HEK293 cells co-
transfected with HER2 fused to the YFP Venus N-terminal (n-YFP) and CB2R fused to 
the YFP Venus C-terminal (c-YFP) were treated with vehicle, the CB2R mutants or the 
indicated TAT-TM peptides (4 μM) for 4 h at 37 °C. Fluorescence at 530nm (which only 
appears after YFP complementation due to proximity of the two receptors fused to 
cYFP and nYFP hemiproteins) was quantified in a Fluo Star Optima Fluorimeter (BMG 
Labtechnologies). Protein fluorescence expression was determined as fluorescence of 
the sample minus fluorescence of non-transfected cells. Cells expressing HER2-n-YFP 
and n-YFP or CB2R-c-YFP and c-YFP showed similar fluorescence levels to non-
transfected cells. 
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Antibody-capture [35S]GTPγS scintillation proximity assays (SPA) . Specific 
activation of different subtypes of Gα-proteins by THC (5 µM) was determined as 
previously described (46). Briefly, cell membrane homogenates from the four different 
cell lines [HEK293 cells transiently overexpressing HER2, CB2R, both receptors 
(HER2-CB2R) simultaneously or the corresponding empty vector (pcDNA3)] were 
incubated in 96-well Isoplates (Perkin Elmer Life Sciences, Waltham, MO) in incubation 
buffer containing 0.4 nM [35S]GTPγS (Perkin Elmer) and 50 or 100 μM GDP for Gi2, 
Gq/11 and Go, or for Gi1,Gi3, Gz, Gs and G12/13 proteins, respectively. Specific antibodies 
for each Gα subunit (mouse monoclonal anti-Gαi1 and anti-Gαo, and rabbit polyclonal 
anti-Gαi2, anti-Gαi3, anti-Gαz, anti-Gαq/11, anti-Gαs, and anti-Gα12/13; Santa Cruz 
Biotechnologies) and PVT SPA beads coated with protein A (Perkin Elmer) were used. 
Radioactivity was quantified on a MicroBeta TriLux scintillation counter (Perkin Elmer). 
 
Animals and treatments. All procedures involving animals were performed with the 
approval of the Complutense University Animal Experimentation Committee and 
Madrid Regional Government, according to the European official regulations. For the 
generation of orthotopic tumors, 5x106 HCC1954 cells were injected into the fourth right 
mammary fat pad of anesthetized (with 4% isoflurane) 6 week-old SCID female mice 
(Envigo, Barcelona, Spain). Tumor volume was routinely measured with and external 
caliper, and when it reached an average volume of 200mm3, animals were randomly 
assigned to the different experimental groups: THC (1.5mg/animal/dosis) or sesame oil 
as vehicle. Treatments were administered orally by gavage in 100uL, 3 times a week 
for 1 month. At the end of the treatment, animals were sacrificed and tumors and 
organs were collected. Tumors were divided in portions for preparation of tissue 
sections for PLA staining (frozen in Tissue-Tek) and protein extraction (snap frozen), 
and were stored at -80°C until analysis. For PLA experiments, tumor samples were 
fixed by immersion in 4% paraformaldehyde solution for 24 h at 4°C, washed in PBS 
and cryopreserved in a 30% sucrose solution at 4°C. Before sectioning, tumors were 
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frozen in tissue-tek, and 20µm thick-slices were cut on a freezing cryostat (Leica Jung 
CM-3000) and mounted on slide glass. 
 
Patient-Derived Xenografts (PDX). Human breast tumors used to establish (PDX) 
were from biopsies or surgical resections at Vall d'Hebron University Hospital 
(Barcelona, Spain), and were obtained following institutional guidelines and approval of 
the institutional review boards (IRB) at Vall d’Hebron Hospital in accordance with the 
Declaration of Helsinki. Written informed consent was obtained from all patients who 
provided tissue. Fragments of patient samples were implanted into the mammary fat 
pad of NOD.CB17-Prkdcscid (NOD/SCID) (#SM-NOD-5S-F, Janvier, France) and 
maintained with 17 ß-estradiol (1 μM) (#E8875-1G, Sigma) in the drinking water. Mice 
were maintained and treated in accordance with institutional guidelines of Vall 
d’Hebron University Hospital Care and Use Committee. 
 
Tissue Microarray (TMA). Two different tumor series, in a tissue microarray (TMA) 
format, were used in this study. TMA #1 consisted of 57 samples corresponding to 
newly diagnosed HER2+ breast cancer patients operated at 12 de Octubre University 
Hospital (Madrid, Spain) between 1999 and 2013, and prior any treatment. TMA #2 
was previously described in (47), and contained 138 high-grade ductal breast cancer 
samples obtained before treatment at the Vall d´Hebron Hospital (Barcelona, Spain), 
Virgen del Rocío Hospital (Seville, Spain), and MD Anderson Cancer Center (Madrid, 
Spain), between 2003 and 2014. Of them, 39 corresponded to HER2+ cases. In both 
cases, PFA-fixed and paraffin-embedded blocks of tumor tissue were used to generate 
the corresponding TMAs by punching two 1-mm spots of each patient’s biopsy. 
 
Statistics. Kaplan-Meier survival curves were statistically compared by the log-rank 
test. The best cut-off was manually selected for each TMA. In TMA #1, the PLA signal 
ranged from 1.3 to 16.0, and the cut-off was set at 8.0. In TMA#2, the PLA signal 
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ranged from 1.5 to 6.0, and the cut-off was set at 4.0. Unpaired, independent groups of 
2 were analyzed by 2-tailed Student’s t test. When multi-group comparison was 
required, data were analyzed by 1-way ANOVA with Tukey’s post hoc test. Tumor 
growth curves from vehicle and THC-treated animals were statistically compared by 2-
way-ANOVA. Significance level was below 0.05 in all cases. Results are shown as 
mean ± SEM, and the number of experiments is indicated in every case. All analyses 
were carried out using GraphPad software, Inc.  
 
Data supporting the findings of this study are available within the paper and its SI 
Appendix. Detailed protocols and materials can be requested to the corresponding 
authors. 
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Figure legends 
 
Fig. 1. HER2-CB2R heteromer expression correlates with poor patient prognosis. 
Proximity Ligation Assays (PLAs) were performed in Tissue Microarrays (TMAs) and 
Patient-Derived Xenografts (PDX). Scale bars, 25µm. For the TMAs, samples were 
ranked based on HER2-CB2R heteromer expression (i.e. PLA signal), and the best cut-
off was manually selected. (A) Representative confocal microscopy images of a low- 
and a high-heteromer expressing sample in TMA #1. The red dotted signal 
corresponds to the heteromers, and the blue staining to cell nuclei. (B-D) Kaplan-Meier 
curves for disease-free survival [from samples included in TMA #1 (n=57) (B), or TMA 
#2 (n=39) (C)] and overall patient survival [from the HER2+ samples included in TMA 
#2 (n=33) (D)]. Curves were statistically compared by the log-rank test (*, P <0.05). (E, 
F) Upper panels, representative images of HER2-CB2R heteromer expression in two 
pairs of PDX, consisting of a PDX established from the patient’s primary tumor and a 
sample derived from a metastasis in the same patient [in the liver in one case, (E), and 
in a lymph node in the other (F)]. Lower panels, quantification of HER2-CB2R 
heteromer expression in the PDX samples. Results are expressed as PLA ratio 
(number of red dots per cell), and error bars represent SEM (n=7 technical replicates in 
primary tumor samples and n=5 in metastatic samples). 
 
Fig. 2. THC decreases HER2-CB2R complexes. (A) Schematic representation of 
Bioluminiscence Resonance Energy Transfer (BRET) experiments. (B) BRET 
saturation curve in HEK293 cells transfected with a fixed concentration of HER2-Rluc 
and increasing concentrations of CB2R-YFP. HER2-Rluc/GHS-R1a-YFP and D44R-
Rluc/YFP were used as negative controls for the interaction (n=8). (C) Effect of THC (4 
h), alone or in combination with the CB2R-selective antagonist SR1414528 (SR2, 1 
µM), on HER2-Rluc/CB2R-YFP BRETmax signal in HEK293 cells (n=3). (D, E) Viability 
of CB2R and HER2 transfected-HEK293 cells after 24 h treatment with increasing 
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concentrations of THC (n=5) (D), or THC in combination with SR2 (1 μM) (n=4) (E). (F, 
G) Viability of BT474 (n=6) and HCC1954 (n=3) cells in response to increasing 
concentrations of THC (F), or in combination with the CB2R-selective antagonist 
SR144528 (SR2, 1μM) (G). Results (n=3-6 independent experiments) are expressed 
as % vs vehicle-treated cells, set at 100%, and error bars represent SEM. (H) Co-
immunoprecipitacion of HER2 with CB2R after THC treatment (4 h), in BT474 and 
HCC1954 cells transfected with a HA-tagged CB2R plasmid. (I) Representative PLA 
confocal microscopy images of HER2-CB2R heteromers (in red) in BT474 (upper 
panels) and HCC1954 cells (lower panels), treated with THC (4 h) alone or in 
combination with SR2 (1 μM). Cell nuclei are stained in blue. Scale bars: 25µm. (J) 
Quantification of HER2-CB2R PLA signal (number of red dots per cell), (n=3). Results 
are expressed as % vs vehicle-treated cells, set at 100 % and error bars represent 
SEM. Multigroup comparisons were analyzed by One-way ANOVA with Tukey’s post 
hoc test. *, P <0.05; **, P <0.01 vs vehicle-treated cells; #, P <0.05; ##, P <0.01 vs 
THC. 
 
Fig. 3. HER2-CB2R heteromer disruption by THC hampers HER2 activation. (A) HER1, 
HER2, HER3 and HER4 expression, as determined by Western blot analysis, in the 
indicated breast cancer cell lines. (B) Representative PLA confocal miscroscopy 
images of the effect of THC (4 h) on HER2-HER1 (n=4), HER2-HER2 (n=5) and HER2-
HER3 (n=3) dimers (in red) in HCC1954 cells (B), with the corresponding quantification 
(C), or on HER2-HER2 expression after THC treatment, alone or in combination with 
the CB2R-selective antagonist SR144528 (SR2, 1 μM) (n=3) (D), with the 
corresponding quantification (E). Cell nuclei are in blue. Scale bars: 20 µm. (F, G) Left 
panels, schematic representation of the BRET experiments conducted in HEK293 cells. 
CoH: coelenterazine H. Right panels, quantification of HER2-Rluc/HER2-YFP BRETmax 
after THC treatment (4 h) alone or in combination with SR2 (1 µM) where indicated, in 
cells co-transfected with HER2-Rluc, HER2-YFP and a CB2R untagged receptor (n=3) 
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(F), or an empty vector (n=4) (G) (used as a negative control for THC activation). In (C, 
E, F and G) results are expressed as % vs vehicle-treated cells, set as 100 % and 
graph bars represent SEM. (H) Expression of pHER21248 in BT474 and HCC1954 cells, 
as determined by Western blot, upon THC treatment at the indicated times, and (I) 
quantification. Results are normalized vs the corresponding total HER2 levels at each 
individual time point, and expressed as fold increase vs time 0, set at 1 (n=4 in BT474, 
and n=7 in HCC1954)). Unpaired independent groups of 2 were analyzed by 2-tailed 
Student’s t test. When multi-group comparison was required, data were analyzed by 
One-way ANOVA with Tukey’s post hoc test. *, P <0.05; **, P <0.01 vs vehicle-treated 
cells; ##, P <0.01 vs THC. 
 
Fig. 4. HER2-CB2R heteromer disruption by THC induces HER2 degradation in vitro 
and in vivo. Effect of THC on HER2 protein (A, B) and mRNA levels (D) at the indicated 
times, as determined by Western blot and Q-PCR, respectively, in BT474 and 
HCC1954 cells. For quantification, HER2 expression was normalized with the loading 
control [β-Actin in (B), and β-Actin and GUSB in (D)], and results (n=4 in B and n=3 in 
D) expressed as fold increase vs time 0, set at 1. graph bars represent SEM. Data 
were analyzed by one-way ANOVA. (C) Western blot analysis of the effect of the 
CB2R-selective antagonist SR144528 (SR2, 1 μM) on THC-induced HER2 protein 
decrease (n=4 in BT474 and n=7 in HCC1954). (E) Growth of orthotopic tumors 
generated in NOD-SCID mice by injection of HCC1954 cells in the mammary fat pad. 
Animals were treated with vehicle (sesame oil) (n=10) or THC (1.5 mg/dose) (n=9) 
thrice a week. Results were analyzed by two-way ANOVA. (F) Representative Western 
blot of HER2 in the animal tumor samples, with the corresponding quantification (G). 
(H) Representative PLA confocal microscopy images of HER2-CB2R and HER2-HER2 
heteromers (red signal), and quantification (I). Cell nuclei are in blue. Scale bar, 50µm. 
Unpaired, 2-tailed Student’s t test. *, P <0.05; **, P <0.01 vs time 0 (B) or vehicle-
treated animals in (E, G, I).  
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Fig. 5. HER2-CB2R heteromer disruption by THC induces HER2 degradation via the c-
CBL E3 ligase. Western blot-based analyses of the effect of different pharmacological 
and genetic tools on THC-induced HER2 degradation. (A, B) Effect of lactacystin (LAC, 
1 µM) on BT474 cells (n=4). Effect of THC (4 h) on ubiquitinated HER2 (C), on c-CBL 
and CHIP levels (D, E), or on HER2 phosphorylation at Tyr 1112 (F), in the indicated 
breast cancer cell lines. (G, H) HER2 protein expression after genetic silencing of c-
CBL with selective siRNAs (siCBL). A non-targeted siRNA was used as a control (siC). 
The densitometric analyses of HER2 immunoblots were normalized to β-Actin (n=4 in 
B, n=6 in E, n=4 in H). Results are expressed as fold increase vs vehicle-treated cells, 
set at 1, and graph bars represent SEM. Unpaired, independent groups of 2 were 
analyzed by 2-tailed Student’s t test. When multi-group comparison was required, data 
were analyzed by One-way ANOVA with Tukey’s post hoc test. *, P <0.05; **, P <0.01 
vs vehicle-treated group; #, P <0.05; ##, P <0.01 vs THC-treated group. 
 
Fig. 6. CB2R transmembrane domain 5 is involved in HER2-CB2R heterodimerization. 
(A) Schematic representation of the HA-tagged truncated forms of CB2R used in this 
study. Each construct contains the HA tag, followed by the N-terminal domain of the 
receptor, one of its 7 transmembrane domains, and the C-terminal end. (B) Each of the 
7 CB2R constructs (named as HA-TMX, where X is the corresponding transmembrane 
domain) and a pcDNA3-HER2 plasmid were co-expressed in HEK293 cells. 
Immunoprecipitation of HER2 with an anti-HER2 antibody was followed by Western 
blot analysis with an anti-HA antibody. Full length pcDNA3-HA-CB2R was also co-
expressed with HER2 as a positive control of interaction. (C) Schematic representation 
of the Bimolecular Fluorescence Complementation (BiFC) experiments between HER2-
cYFP and CB2R-nYFP in the absence (upper panel) or in the presence of the CB2R 
transmembrane constructs (lower panel). (D, E) Complementation signal (i.e. 
fluorescence at 530nm) of HEK293 cells transfected with CB2R-cYFP, HER2-nYFP and 
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the indicated CB2R TM constructs (n=3) (D), or after 4h of incubation with the indicated 
TAT-TM peptides (4µM) (n=3) (E). Results were analyzed by One-way ANOVA with 
Tukey’s post hoc test. **, P <0.01 vs pcDNA3 (D) or vehicle-treated group (E). 
 
Fig. 7. HER2-CB2R heteromer disruption by targeting CB2R TM5 mimics THC effects. 
(A-D) Effect of TM peptides on HER2-CB2R and HER2-HER2 heteromer expression as 
determined by PLA. (A, C) Representative PLA images in the indicated breast cancer 
cell lines, after treatment for 4 h with vehicle (DMSO), a TAT-TM peptide targeting 
CB2R TM5 (4 μM), or a TAT-TM peptide targeting dopamine receptor D44 (4 μM), used 
as a negative control. Dimer signal is in red, and cell nuclei in blue. Scale bars: 25 µm. 
(B, D) Results (n=7 technical replicates) are expressed as % of PLA (red dots per cell) 
vs vehicle-treated cells, set as 100 %. (E) pHER21248 and HER2 protein levels, as 
determined by Western blot, after treatment with vehicle, CB2R TAT-TM5 or D44R 
TAT-TM5 peptides for 24 h in BT474 and HCC1954 cells. (F) Densitometric analysis of 
HER2 normalized to β-Actin (n=3). Results are represented as fold increase vs vehicle-
treated cells, set as 1. (G) Viability of HCC1954, BT474 and HEK293 cells in response 
to the indicated treatments for 24 h. Data (n=4) are represented as % vs vehicle-
treated cells, set as 100 %, and graph bars represent SEM. One-way ANOVA with 
Tukey’s post hoc test. **, P <0.01 vs vehicle-treated cells. 
 
Fig. 8. Schematic drawing of the proposed mechanism of control of HER2 activity by 
CB2R. (A) HER2 forms heteromers with CB2R at the plasma membrane of HER2+ 
breast cancer cells, protecting it from degradation and favoring its pro-oncogenic 
signaling. (B) Disruption of HER2-CB2R heteromers, either by THC or by specific tools 
targeting CB2R transmembrane domain 5, triggers inactivation of HER2 by inducing the 
separation of HER2-HER2 homodimers, and increasing HER2 susceptibility to 
degradation by the E3-ligase c-CBL. HER2 degradation and CB2R activation result in 
antitumor responses.  
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